Boston Biomedical Innovation Center

波士顿生物医学创新中心

• 批准号: 9140777
• 负责人: DAVID E. GOLAN
• 金额: $ 106.2万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9140777
• 关键词: Academia; Achievement; Address; Biological Sciences; Biomedical Technology; Blood; Boston; Cardiovascular system; Clinical; Communities; Decision Making; Development; Devices; Diagnostic; Elements; Ensure; Environment; Funding; Goals; Government Agencies; Healthcare; Heart; Heart Diseases; Hematological Disease; Hematology; Individual; Institution; Knowledge; Lung; Lung diseases; Medical; Medicine; Mentors; Mission; National Heart, Lung, and Blood Institute; Patients; Private Sector; Process; Public Sector; Rare Diseases; Research Infrastructure; Research Personnel; Resources; Rewards; Secure; Seeds; Sleep; Sleep Disorders; Societies; Speed; Staging; Technology; Therapeutic; Time; Translational Research; Translations; clinical application; clinical practice; commercialization; experience; innovation; meetings; new technology; public-private partnership; skills; success; tool; validation studies

A well-recognized gap exists in the path from biomedical discovery in academia to clinical application and commercialization of therapeutic, device, and diagnostic technologies in cardiovascular, pulmonary, hematologic, and sleep disorders. This chasm is the result of inadequate funding for support of proof-of-concept or validation studies essential for early stage development; insufficient access to the resources and expertise needed to develop new technologies; and a lack of knowledge and experience among academic investigators in bringing new ideas to commercial realization. Within the partnering institutions included in this application, the essential elements exist with which to build the infrastructure needed to support and sustain the uninterrupted, durable flow of inventions from discovery through development and commercialization. While these institutions have a clear track record of remarkably successful development of many biomedical technologies, most of these commercial successes have been achieved by the tenacity of individual inventors rather than with the help of committed institutional mechanisms. We proposed to address these key shortcomings by establishing the regional Boston Center for Accelerated Innovation in Therapeutics, Devices, and Diagnostics for Heart, Lung, Blood, and Sleep Disorders (B-BIC, or the Boston Biomedical Innovation Center). The key objectives of this Center are to: 1) develop an integrated infrastructure that would expand the universe of commercializable technologies for heart, lung, blood, and sleep disorders; 2) place these opportunities in the proper evaluative context through an engagement ("seed it"), solicitation ("find it"), and selection ("pick it") strategy; 3) efficiently and effectively bring those selected to an appropriate exit point from the development process; and 4) provide the educational and mentoring infrastructure necessary for the development of the proper entrepreneurial skills among academic innovators. By achieving these goals, B-BlC would change the culture of our academic environment, as well as the relationship between the public and private sectors in facilitating successful development strategies for technologies in heart, lung, blood, and sleep disorders for the ultimate benefit of patients and society.

从学术界的生物医学发现到临床应用， 在心血管，肺， 血液和睡眠障碍这一鸿沟是概念验证支持资金不足的结果 或验证研究对早期发展至关重要;资源获取不足， 开发新技术所需的专业知识;学术界缺乏知识和经验 研究人员将新的想法带到商业实现中。在伙伴机构内， 这个应用程序，基本要素存在，以建立所需的基础设施，以支持和 保持发明从发现到发展的不间断、持久的流动， 商业化虽然这些机构有着非常成功的发展的明确记录 在许多生物医学技术中，大多数商业上的成功都是由坚韧的 个人发明家的帮助，而不是在承诺的机构机制的帮助下。我们建议 通过建立区域性的波士顿加速创新中心， 心脏、肺、血液和睡眠障碍的治疗、设备和诊断（B-BIC，或波士顿 生物医学创新中心）。该中心的主要目标是：1）建立一个综合的 基础设施，这将扩大心脏，肺，血液和 睡眠障碍; 2）通过参与（“种子”）将这些机会置于适当的评估环境中 它”），征求（“找到它”），和选择（“挑选它”）战略; 3）高效和有效地使那些选择， 从发展过程中适当的退出点;以及4）提供教育和指导 在学术界发展适当的创业技能所需的基础设施 创新者通过实现这些目标，B-BLC将改变我们的学术环境的文化， 以及公营和私营部门在促进成功发展方面的关系 心脏、肺、血液和睡眠障碍的技术战略，以最终造福患者和社会。